Estimation of the Youden Index and its associated cutoff point.
Ronen Fluss, David Faraggi, Benjamin Reiser
https://pubmed.ncbi.nlm.nih.gov/16161804/Actively Recruiting
Led by Brigham and Women's Hospital · Updated on 2026-03-02
150
Participants Needed
2
Research Sites
13 weeks
Total Duration
This research aims to evaluate the use of endoscopic ultrasound shear wave elastography EUS-SWE as a screening tool for liver fibrosis in patients with elevated body mass index BMI and non-alcoholic fatty liver disease NAFLD. It compares EUS-SWE accuracy to other non-invasive methods like the FIB-4 score and Fibroscan. The study also seeks to establish optimal liver stiffness cutoffs for EUS-SWE in this group, referencing liver biopsy as the gold standard, since no standard cutoffs currently exist. Participants undergoing routine endoscopic ultrasound as part of their clinical care will have the shear wave elastography added, which takes an extra 2-3 minutes without added risk or radiation exposure. The device used is an FDA-approved linear EUS endoscope with SWE features. Liver biopsy samples are obtained either during the same session or within six months of the ultrasound. Data including demographics, lab results, elastography, and biopsy findings are collected prospectively. During the study, participants will undergo the endoscopic ultrasound with shear wave elastography. Researchers will gather clinical, imaging, and biopsy data to analyze EUS-SWE accuracy and determine stiffness cutoffs for fibrosis grading. The primary outcomes include assessing EUS-SWE accuracy compared to biopsy and establishing stiffness thresholds. The study follows participants up to six months, ensuring privacy and secure data management throughout the process.
CONDITIONS
Endoscopic Ultrasound Shear Wave Elastography in Patients With Non-alcoholic Fatty Liver Disease
P
Peter Konyn, MD
M
Michele Ryan
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Brigham and Women's Hospital
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Same day as screening or within 6 months
Participants undergo clinically indicated endoscopic ultrasound (EUS) with shear wave elastography to assess liver stiffness for fibrosis screening.
1 visit (in-person)
Duration - Up to 6 months
Participants' data including demographics, laboratory findings, elastography, and liver biopsy results are collected and observed for up to 6 months to assess the accuracy of the EUS-SWE device.
Follow-up visits as clinically indicated
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Have more questions? Get in touch with our team for quick support
Ronen Fluss, David Faraggi, Benjamin Reiser
https://pubmed.ncbi.nlm.nih.gov/16161804/Yoshio Sumida, Atsushi Nakajima, Yoshito Itoh
https://pubmed.ncbi.nlm.nih.gov/24574716/Guangqin Xiao, Sixian Zhu, Xiao Xiao...
https://pubmed.ncbi.nlm.nih.gov/28586172/Thomas J Wang, Pichamol Jirapinyo, Raj Shah...
https://pubmed.ncbi.nlm.nih.gov/39481576/Magdalena Eilenberg, Petra Munda, Judith Stift...
https://pubmed.ncbi.nlm.nih.gov/34760965/Fabrizio Termite, Federica Borrelli de Andreis, Antonio Liguori...
https://pubmed.ncbi.nlm.nih.gov/39601324/Robert P Myers, Gilles Pomier-Layrargues, Richard Kirsch...
https://pubmed.ncbi.nlm.nih.gov/21898479/Brigham and Women's Hospital
Lead Sponsor